Clinical application of anti-ccr4 monoclonal antibody

Oncology (Switzerland)

Volumn 89, Issue , 2015, Pages 16-21

  Ueda, Ryuzo ^a  

^a AICHI MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

Adult t cell leukemia; Anti ccr4 antibody; Antibody dependent cellular cytotoxicity; Ccr4; Mogamulizumab; Potelligent technology; Regulatory t cells; Regulatory t cell depletion; Tumor immunotherapy

Indexed keywords

CANCER TESTIS ANTIGEN; CD4 ANTIGEN; CD45RA ANTIGEN; CHEMOKINE RECEPTOR CCR4; FC RECEPTOR; MOGAMULIZUMAB; NY ESO 1 ANTIGEN; TRANSCRIPTION FACTOR FOXP3; ANTINEOPLASTIC AGENT; CCR4 PROTEIN, HUMAN; MONOCLONAL ANTIBODY;

ADULT T CELL LEUKEMIA; ADVANCED CANCER; ANAPLASTIC LARGE CELL LYMPHOMA; ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; BINDING AFFINITY; CANCER IMMUNOTHERAPY; CANCER RECURRENCE; CUTANEOUS T CELL LYMPHOMA; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; EFFECTOR CELL; ESOPHAGUS CANCER; EXTRANODAL NATURAL KILLER/T-CELL LYMPHOMA; HODGKIN DISEASE; HUMAN; IMMUNE RESPONSE; LARGE CELL LYMPHOMA; LONG TERM SURVIVAL; LUNG CANCER; LYMPHOBLASTOMA; LYMPHOCYTE DEPLETION; MYCOSIS FUNGOIDES; OVERALL SURVIVAL; PERIPHERAL T CELL LYMPHOMA; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; PROTEIN EXPRESSION; RASH; REGULATORY T LYMPHOCYTE; SOLID MALIGNANT NEOPLASM; T CELL LEUKEMIA; TUMOR ESCAPE; TUMOR IMMUNITY; TUMOR MICROENVIRONMENT; TUMOR REGRESSION; ANTAGONISTS AND INHIBITORS; DRUG EFFECTS; GENE EXPRESSION REGULATION; HEMATOLOGIC NEOPLASMS; IMMUNOLOGY; LEUKEMIA-LYMPHOMA, ADULT T-CELL; LYMPHOMA, T-CELL, PERIPHERAL; METABOLISM;

ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE I AS TOPIC; GENE EXPRESSION REGULATION, NEOPLASTIC; HEMATOLOGIC NEOPLASMS; HUMANS; LEUKEMIA-LYMPHOMA, ADULT T-CELL; LYMPHOMA, T-CELL, PERIPHERAL; RECEPTORS, CCR4; T-LYMPHOCYTES, REGULATORY; TUMOR ESCAPE; TUMOR MICROENVIRONMENT;

EID: 84960977602     PISSN: 00302414     EISSN: 14230232     Source Type: Journal    
DOI: 10.1159/000431059     Document Type: Article

References (24)

1. Pardoll DM: The blockade of immune checkpoints in cancer immune therapy. Nat Rev Cancer 2012; 12: 252-264.
2. Sznol M, Longo DL: Release the hounds! Activating T-cell response to cancer. N Engl J Med 2015; 372: 374-375.
3. Imai T, Nagira M, Takagi S, Kakizaki M, Nishimura M, Wang J, Gray PW, Matsushima K, Yoshie O: Selective recruitment of CCR4-bearing Th2 cells toward antigen-presenting cells by the CC chemokines thymus and activation-regulated chemokine and macrophagederived chemokine. Int Immunol 1999; 11: 81-88.
4. Ishida T, Utsunomiya, A, Iida S, Inagaki H, Takatsuka Y, Kusumoto S, Takeuchi G, Shimizu S, Ito M, Komatsu H, Wakita A, Eimoto T, Matsushima K, Ueda R: Clinical significance of CCR4 expression in adult T-cell leukemia/lymphoma: its close association with skin involvement and unfavorable outcome. Clin Cancer Res 2003; 9: 3625-3634.
5. Ishida T, Inagaki H, Utsunomiya A, Takatsuka Y, Komatsu H, Iida S, Takeuchi G, Eimoto T, Nakamura S, Ueda R: CXC chemokine receptor 3 and CC chemokine receptor 4 expression in T-cell and NK-cell lymphomas with special reference to clinicopathological significance for peripheral T-cell lymphoma, unspecified. Clin Cancer Res 2004; 10: 5494-5500.
6. Matsuoka M, Jeang KT: Human T-cell leukaemia virus type 1 (HTLV-1) infectivity and cellular transformation. Nat Rev Cancer 2007; 7: 270-280.
7. Iwanaga M, Watanabe T, Yamaguchi K: Adult T-cell leukemia: A review of epidemiological evidence. Front Microbiol 2012; 3: 1-13.
8. Uchiyama T, Yodoi J, Sagawa K, Takatsuki K, Uchino H: Adult T-cell leukemia: clinical and hematologic features of 16 cases. Blood 1977; 50: 481-492.
9. Shimoyama M: Diagnostic criteria and classification of clinical subtypes of adult T-cell leukaemia-lymphoma. A report from the Lymphoma Study Group (1984-87). Br J Haematol 1991; 79: 428-437.
10. Utsunomiya A, Choi I, Chihara D, Seto M: Recent advances in the treatment of adult T-cell leukemia-lymphomas. Cancer Sci 2015; 106: 344-351.
11. Shinkawa T, Nakamura K, Yamane N, Shoji-Hosaka E, Kanda Y, Sakurada M, Uchida K, Anazawa H, Satoh M, Yamasaki M, Hanai N, Shitara K: The absence of fucose but not the presence of galactose or bisecting N-Acetylglucosamine of human IgG1 complex-Type oligosaccharides shows the critical role of enhancing antibody-dependent cellular cytotoxicity. J Biol Chem 2003; 31: 278: 3466-3473.
12. Niwa R, Hosaka SE, Sakurada M, Shinkawa T, Uchida K, Nakamura K, Matsushima K, Ueda R, Hanai N, Shitara K: Defucosylated chimeric anti-CC chemokine receptor 4 IgG1 with enhanced antibody-dependent cellular cytotoxicity shows potent therapeutic activity to T-cell leukemia and lymphoma. Cancer Res 2004; 64: 2127-2133.
13. Ishii T, Ishida T, Utsunomiya A, Inagaki A, Yano H, Komatsu H, Iida S, Imada K, Uchiyama T, Akinaga S, Shitara K, Ueda R: Defucosylated humanized anti-CCR4 monoclonal antibody KW-0761 as a novel immunotherapeutic agent for adult T-cell leukemia/lymphoma. Clin Cancer Res 2010; 16: 1520-1531.
14. Ishida T, Iida S, Akatsuka Y, Ishii T, Miyazaki M, Komatsu H, Inagaki H, Okada N, Fujita T, Shitara K, Akinaga S, Takahashi T, Utsunomiya A, Ueda R: The CC chemokine receptor 4 as a novel specific molecular target for immunotherapy in adult T-Cell leukemia/lymphoma. Clin Cancer Res 2004; 10: 7529-7539.
15. Ito A, Ishida T, Utsunomiya A, Sato F, Mori F, Yano H, Inagaki A, Suzuki S, Takino H, Ri M, Kusumoto S, Komatsu H, Iida S, Inagaki H, Ueda R: Defucosylated anti-CCR4 monoclonal antibody exerts potent ADCC against primary ATLL cells mediated by autologous human immune cells in NOD/Shi-scid, IL-2R gamma(null) mice in vivo. J Immunol 2009; 183: 4782-4791.
16. Yamamoto K, Utsunomiya A, Tobinai K, Tsukasaki K, Uike N, Uozumi K, Yamaguchi K, Yamada Y, Hanada S, Tamura K, Nakamura S, Inagaki H, Ohshima K, Kiyoi H, Ishida T, Matsushima K, Akinaga S, Ogura M, Tomonaga M, Ueda R: Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemialymphoma and peripheral T-cell lymphoma. J Clin Oncol 2010; 28: 1591-1598.
17. Ishida T, Joh T, Uike N, Yamamoto K, Utsunomiya A, Yoshida S, Saburi Y, Miyamoto T, Takamoto S, Suzushima H, Tsukasaki K, Nosaka K, Fujiwara H, Ishitsuka K, Inagaki H, Ogura M, Akinaga S, Tomonaga M, Tobinai K, Ueda R: Defucosylated anti-CCR4 monoclonal antibody (KW-0761) for relapsed adult T-cell leukemia-lymphoma: A multicenter phase II study. J Clin Oncol 2012; 30: 837-842.
18. Ogura M, Ishida T, Hatake K, Taniwaki M, Ando K, Tobinai K, Fujimoto K, Yamamoto K, Miyamoto T, Uike N, Tanimoto M, Tsukasaki K, Ishizawa K, Suzumiya J, Inagaki H, Tamura K, Akinaga A, Tomonaga M, Ueda R: Multicenter phase II study of mogamulizumab (KW-0761), a defucosylated anti-CCR4 antibody, in patients with relapsed peripheral Tcell lymphoma and cutaneous T-cell lymphoma. J Clin Oncol 2014; 32: 1157-1163.
19. Ishida T, Jo T, Takemoto S, Suzushima H, Uozumi K, Yamamoto K, Uike N, Saburi Y, Nosaka K, Utsunomiya A, Tobinai K, Fujiwara H, Ishitsuka K, Yoshida S, Taira N, Moriuchi Y, Imada K, Miyamoto T, Akinaga S, Tomonaga M, Ueda R: Dose-intensified chemotherapy alone or in combination with mogamulizumab in newly diagnosed aggressive adult T-cell leukaemia-lymphoma: A randomized phase II study. Br J Haematol 2015; 169: 672-682.
20. Miyara M, Yoshioka Y, Kitoh A, Shima T, Wing K, Niwa A, Parizot C, Taflin C, Heike T, Valeyre D, Mathian A, Nakahata T, Yamaguchi T, Nomura T, Ono M, Amoura Z, Gorochov G, Sakaguchi S: Functional delineation and differentiation dynamics of human CD4+ T cells expressing the FoxP3 transcription factor. Immunity 2009; 30: 899-911.
21. Sugiyama D, Nishikawa H, Maeda Y, Nishioka M, Tanemura A, Katayama I, Ezoe S, Kanakura Y, Sato E, Fukumori Y, Karbach J, Jager E, Sakaguchi S: Anti-CCR4 mAb selectively depletes effector-Type FoxP3+CD4+ regulatory T cells, evoking antitumor immune responses in humans. Proc Natl Acad Sci USA 2013; 110: 17945-17950.
22. Ishida T, Ueda R: Immunopathogenesis of lymphoma: focus on CCR4. Cancer Sci 2011; 102: 44-50.
23. Ishida T, Ueda R: CCR4 as a novel molecular target for immunotherapy of cancer. Cancer Sci 2006; 97: 1139-1146.
24. Kurose K, Ohue Y, Wada H, Iida S, Ishida T, KojimaT, Doi T, Suzuki S, Isobe M, Funakoshi T, Kakimi K, Nishikawa H, Udono H, Oka M, Ueda R, Nakayama E: Phase Ia study of FoxP3. CD4 Treg depletion by infusion of a humanized anti-CCR4 antibody, KW-0761, in cancer patients. Clin Cancer Res 2015;21:4327-4336.